When was PROTEOR acquired by ARDIAN / BNP PARIBAS DEVELOPPEMENT?

PROTEOR was acquired by ARDIAN / BNP PARIBAS DEVELOPPEMENT in 2021.

What was the revenue of PROTEOR at the time of the deal?

The revenue of PROTEOR at the time of the deal is estimated to be in the range of 100M - 200M EUR.

What was the EBITDA of PROTEOR during the acquisition?

PROTEOR's EBITDA is estimated to be in the range of 5M - 25M EUR.

How is the data for the PROTEOR acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PROTEOR deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/proteor-leader-francais-de-lorthopedie-externe-accueille-ardian-et-bnp#:~:text=Paris%2C%2013%20janvier%2C%202021%20%E2%80%93,partenaires%20pour%20l'accompagner%20dans

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaPROTEOR

01/2021

PROTEOR acquired by ARDIAN & BNP PARIBAS DEVELOPPEMENT

FRANCE Life Sciences / MedTech / Implants & Prosthetics REV 100M - 200M EUR

Context

For the first time since its founding in 1913, Proteor has opened its capital to institutional investors through a primary Owner Buy-Out (OBO). Ardian Growth and BNP Paribas Développement have injected €24 million (a mix of convertible bonds and equity) to support the group's next phase of expansion. The founding Archambeaud family maintains clear majority control of the group. The strategic rationale for this primary round is to provide Proteor with the financial firepower to execute major international build-ups, specifically the $17 million acquisition of the US-based assets of Freedom Innovations. This deal transforms Proteor into a global player in the high-tech prosthetics market, integrating advanced micro-processor technologies and strengthening its footprint in North America.

PROTEOR, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1913, PROTEOR is a world-class leader in the orthotics and prosthetics (O&P) market. The group specializes in high-tech orthopedic components (microprocessor knees, bionic feet) and custom-made medical devices. It operates a dual model combining manufacturing (R&D/Sales) and a large network of specialized care centers in France.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with PROTEOR

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2025	CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENT	PROTEOR	FRANCE	Implants & Prosthetics

REFERENCES

Revenue range: 100M - 200M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PROTEOR by ARDIAN / BNP PARIBAS DEVELOPPEMENT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: proteor

Acquirer: ardian / bnp paribas developpement